| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
68,146 |
44,884 |
$3.95M |
| 90686 |
|
283,278 |
252,777 |
$2.84M |
| 90633 |
|
90,726 |
88,417 |
$1.00M |
| 90670 |
|
88,556 |
87,128 |
$980K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
25,089 |
22,111 |
$872K |
| 90651 |
|
73,894 |
70,553 |
$813K |
| 90707 |
|
68,453 |
66,793 |
$783K |
| 90648 |
|
65,761 |
64,541 |
$781K |
| 90716 |
|
68,414 |
66,748 |
$760K |
| 90715 |
|
58,847 |
55,900 |
$730K |
| 90734 |
|
63,339 |
60,092 |
$671K |
| 90619 |
|
31,126 |
29,402 |
$591K |
| 90723 |
|
49,443 |
48,531 |
$539K |
| 90681 |
|
38,428 |
37,817 |
$431K |
| 90696 |
|
37,323 |
36,285 |
$419K |
| 90698 |
|
27,882 |
27,547 |
$369K |
| 0001A |
|
10,361 |
8,423 |
$346K |
| 0002A |
|
9,166 |
6,992 |
$325K |
| 90700 |
|
29,260 |
28,671 |
$324K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,687 |
2,521 |
$314K |
| 99188 |
|
20,750 |
12,956 |
$213K |
| 90671 |
|
15,048 |
14,885 |
$194K |
| 90697 |
|
11,347 |
11,264 |
$173K |
| 87428 |
|
2,461 |
2,396 |
$166K |
| 90710 |
|
8,586 |
8,356 |
$108K |
| 90713 |
|
8,009 |
7,689 |
$86K |
| 90744 |
|
6,936 |
6,786 |
$76K |
| 91322 |
|
599 |
560 |
$58K |
| 90672 |
|
6,129 |
5,964 |
$47K |
| 0012A |
|
1,390 |
1,210 |
$45K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
15,155 |
13,992 |
$43K |
| 0031A |
|
1,462 |
1,255 |
$42K |
| 0011A |
|
796 |
698 |
$29K |
| 90656 |
|
1,773 |
1,768 |
$26K |
| 0124A |
|
759 |
675 |
$22K |
| 91320 |
|
360 |
334 |
$22K |
| 90480 |
|
566 |
534 |
$19K |
| 0051A |
|
505 |
462 |
$16K |
| 0052A |
|
533 |
478 |
$16K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
934 |
807 |
$12K |
| 90381 |
|
889 |
879 |
$11K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
70 |
70 |
$10K |
| 91321 |
|
262 |
239 |
$9K |
| 0071A |
|
329 |
236 |
$8K |
| 0072A |
|
335 |
235 |
$8K |
| 90714 |
|
1,191 |
1,130 |
$7K |
| 0134A |
|
229 |
189 |
$6K |
| 90380 |
|
451 |
449 |
$6K |
| 0082A |
|
174 |
146 |
$6K |
| 0041A |
|
172 |
154 |
$5K |
| 0154A |
|
146 |
130 |
$5K |
| 0053A |
|
172 |
152 |
$5K |
| 0073A |
|
224 |
139 |
$5K |
| 0081A |
|
100 |
92 |
$4K |
| 0111A |
|
55 |
54 |
$2K |
| 91319 |
|
49 |
49 |
$2K |
| 0112A |
|
33 |
32 |
$1K |
| T1502 |
Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit |
1,282 |
989 |
$1K |
| 90632 |
|
13 |
13 |
$671.56 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
772 |
713 |
$643.86 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
37 |
35 |
$622.31 |
| 0094A |
|
22 |
19 |
$600.00 |
| 90680 |
|
40 |
37 |
$325.04 |
| 91300 |
|
13,220 |
10,946 |
$97.96 |
| 91307 |
|
7,257 |
4,594 |
$42.23 |
| 91301 |
|
2,272 |
1,976 |
$15.28 |
| 91305 |
|
1,411 |
1,241 |
$10.62 |
| 90732 |
|
12 |
12 |
$9.56 |
| 91303 |
|
1,430 |
1,232 |
$9.34 |
| 91312 |
|
778 |
691 |
$5.56 |
| 91308 |
|
397 |
355 |
$3.42 |
| 91313 |
|
229 |
192 |
$1.50 |
| 91311 |
|
163 |
141 |
$1.38 |
| 91315 |
|
147 |
131 |
$1.18 |
| 91309 |
|
35 |
32 |
$0.26 |
| 90461 |
|
33 |
31 |
$0.00 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
244 |
206 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
36 |
36 |
$0.00 |